JP2024540395A5 - - Google Patents

Info

Publication number
JP2024540395A5
JP2024540395A5 JP2024526964A JP2024526964A JP2024540395A5 JP 2024540395 A5 JP2024540395 A5 JP 2024540395A5 JP 2024526964 A JP2024526964 A JP 2024526964A JP 2024526964 A JP2024526964 A JP 2024526964A JP 2024540395 A5 JP2024540395 A5 JP 2024540395A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540395A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/080837 external-priority patent/WO2023079086A1/en
Publication of JP2024540395A publication Critical patent/JP2024540395A/ja
Publication of JP2024540395A5 publication Critical patent/JP2024540395A5/ja
Pending legal-status Critical Current

Links

JP2024526964A 2021-11-05 2022-11-04 Covid-19を治療及び予防するための組成物 Pending JP2024540395A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163276410P 2021-11-05 2021-11-05
US63/276,410 2021-11-05
PCT/EP2022/080837 WO2023079086A1 (en) 2021-11-05 2022-11-04 Composition for treatment and prevention of covid-19

Publications (2)

Publication Number Publication Date
JP2024540395A JP2024540395A (ja) 2024-10-31
JP2024540395A5 true JP2024540395A5 (https=) 2025-11-11

Family

ID=84367072

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526964A Pending JP2024540395A (ja) 2021-11-05 2022-11-04 Covid-19を治療及び予防するための組成物

Country Status (10)

Country Link
US (1) US20230242626A1 (https=)
EP (1) EP4426347A1 (https=)
JP (1) JP2024540395A (https=)
KR (1) KR20240105408A (https=)
CN (1) CN118475367A (https=)
AU (1) AU2022383505A1 (https=)
CA (1) CA3237462A1 (https=)
IL (1) IL312583A (https=)
TW (1) TW202342095A (https=)
WO (1) WO2023079086A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
TW202342510A (zh) 2022-02-18 2023-11-01 英商Rq生物科技有限公司 抗體
US20250289871A1 (en) 2022-04-29 2025-09-18 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CN101613705A (zh) 2002-03-19 2009-12-30 国际植物研究所 在植物中优化聚糖生成
EP2248892B1 (en) 2003-01-22 2015-04-22 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
BRPI0611445A2 (pt) 2005-05-09 2010-09-08 Glycart Biotechnology Ag molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
JP2009526520A (ja) 2006-01-17 2009-07-23 バイオレックス セラピュティックス インク 植物中でのn−グリカンのヒト化及び最適化のための組成物及び方法
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
CN104119438A (zh) 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
BR112012027828A2 (pt) * 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
HRP20240182T1 (hr) * 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
TW202216777A (zh) * 2020-07-10 2022-05-01 美商生質分子控股有限責任公司 四面體抗體
WO2022026592A2 (en) * 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
KR20220020228A (ko) * 2020-08-11 2022-02-18 (주)셀트리온 안정한 약제학적 제제

Similar Documents

Publication Publication Date Title
JP2024540395A5 (https=)
CN110418803B (zh) 抗rsv单克隆抗体配制品
CN114452380B (zh) Il-17抗体的药物产品和稳定液体组合物
JP2023517236A5 (https=)
JP2024016177A5 (https=)
JP7293122B2 (ja) 補体が媒介する疾患および障害を処置するための方法
JP6554155B2 (ja) Il−17アンタゴニストを使用して汎発性膿疱性乾癬(gpp)を処置する方法
JP2020518599A5 (https=)
CN103189074A (zh) 使用il-17拮抗剂治疗类风湿性关节炎的方法
ES2992409T3 (es) Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
JP7467438B2 (ja) 抗rsv抗体の製剤及びその使用方法
JP2021063092A (ja) B型肝炎表面抗原に対する抗体及びその使用
CN107073110A (zh) 使用il‑17拮抗剂抑制银屑病关节炎患者的结构损伤进展
JP2016540761A (ja) 変形性関節症を治療するための組成物及び方法
US20240366597A1 (en) Cancer treatment combinations
CN113518626B (zh) 用于治疗黄热病的方法和组合物
JP2023507981A5 (https=)
TW202120546A (zh) 使用介白素-17(il-17)拮抗劑治療狼瘡性腎炎之方法
TW202034925A (zh) Cdk4/6抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途
JP2022543956A (ja) 安定なアルブビルチド組成物
US20160244520A1 (en) Compositions and methods for treating psoriatic arthritis
TW201842933A (zh) 使用il-17拮抗劑選擇性治療氣喘的方法
CA3115708C (en) Formulations of anti-rsv antibodies and methods of use thereof
JP2023504679A (ja) インターロイキン-17(il-17)アンタゴニストを使用して扁平苔癬を治療する方法
JP2023539736A5 (https=)